Familial Mediterranean Fever News and Research

RSS

Factors associated with diagnostic delay in Familial Mediterranean Fever

EULAR – The European Alliance of Associations for Rheumatology – held its 2023 annual congress in Milan, Italy. One of the abstracts chosen for presentation in the scientific session on Rheumatic and Musculoskeletal diseases (RMDs) in children and young people, focused on the factors associated with diagnostic delay in FMF, using data from the Juvenile Inflammatory Rheumatism (JIR) cohort.

31 May 2023

Colchicine therapy benefits pediatric long COVID patients suffering from recurring fever

Researchers at National Jewish Health found that a subset of children suffering recurring fevers as a result of long COVID-19, benefited from a daily medication treatment commonly used for gout and periodic fever syndrome.

25 Apr 2023

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

COLCORONA study shows that colchicine can reduce complications in certain COVID-19 patients

The Montreal Heart Institute announces that the COLCORONA study results are published today in The Lancet Respiratory Medicine.

28 May 2021

Crafoord Laureate uncovered a new group of rare autoinflammatory diseases

Dan Kastner, USA, has described an entirely new group of rare autoinflammatory diseases. His discoveries have brought new knowledge and led to the development of effective treatments.

1 Feb 2021

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Study reveals molecular pathogenesis of muscular dystrophy-associated cardiomyopathy

In a study recently published in Nature Communications scientists at Okayama University describe the detailed molecular pathogenesis of muscular dystrophy-associated cardiomyopathy in mice lacking the fukutin gene (Fktn), the causative gene for Fukuyama muscular dystrophy.

13 Feb 2020

VIB researchers develop new tool to diagnose Familial Mediterranean Fever

Researchers at VIB and Ghent University have developed a tool to diagnose Familial Mediterranean Fever (FMF).

24 Nov 2016

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.

24 Sep 2016

Research findings may help better understand genetic origins of Familial Mediterranean Fever

A team of scientists led by Stony Brook University researchers have discovered a new mechanism for a bacterial toxin to inhibit inflammation.

19 Sep 2016

ESC publishes new guidelines on pericardial diseases

New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.

29 Aug 2015

Fewer patients take effective gout drug after steep price increase

Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price.

10 Apr 2015

Sophia Genetics obtains CE-IVD mark for routine genetic tests

Sophia Genetics, the European leader in NGS data analysis, has received the CE-IVD mark for genetic testing of Familial Mediterranean Fever and Hypercholeteromia.

24 Sep 2014

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

The University of Texas Health Science at Houston (UTHealth) announced the opening of a center devoted to researching and treating diseases associated with malfunctioning immune systems.

2 Sep 2011

AutoGenomics introduces first automated molecular assay for Familial Mediterranean Fever

AutoGenomics, a leader in providing automated, molecular testing solutions, announced today that it has launched a new test for the identification of genetic mutations implicated in the development of Familial Mediterranean Fever (FMF). The INFINITI® Familial Mediterranean Fever Panel provides simultaneous multiplexed determination of 13 genetic variants common to more than 10 afflicted ethnicities of Mediterranean origin on the automated INFINITI® Analyzer. FMF is prominently present in the Armenian people, Sephardi Jews, Greeks, Arabs and Turks.

21 Dec 2010

Colcrys safe for treating gout flares

Patients who experience gout flares can be treated safely with Colcrys (colchicine, USP), even in the presence of co-morbid conditions that often present physicians with treatment challenges, according to a new analysis presented here at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

9 Nov 2010

Systemic amyloidosis patient to receive triple organ transplant

In 2005, then 40-year-old Walt McGuire was playing hockey twice a week, working full-time and chasing his young daughter. Then one day, he noticed after one trip up the stairs to catch her, he couldn't catch his breath. A few days later his legs were swollen. After numerous trips to different doctors, McGuire finally was diagnosed with a rare blood disorder called amyloidosis.

28 Oct 2010

FDA takes action against unapproved single-ingredient oral colchicine

The U.S. Food and Drug Administration took action against companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of Familial Mediterranean Fever (FMF).

1 Oct 2010

Colcrys Patient Assistance Program introduced by URL Pharma

URL Pharma, Inc. announced the launch of the Colcrys® (colchicine, USP) Patient Assistance Program, an initiative that will allow patients with limited means to save on Colcrys prescriptions. This program reflects URL Pharma's ongoing commitment to helping ensure that all patients who rely on the company's medications are able to access them, regardless of economic status. Colcrys is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever (FMF).

24 Dec 2009

URL Pharma's Colcrys approved by FDA for prevention of gout flares

URL Pharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Colcrys(TM) (colchicine, USP) for the prophylaxis (prevention) of gout flares. Colcrys was first approved by the FDA on July 30, 2009 for the treatment of acute gout flares when taken at the first sign of a flare.

19 Oct 2009